UB Paderborn / Katalog / Suche / in CDI

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

The Lancet (British edition), 2017-07, Vol.390 (10089), p.29-39

2017

Volltextzugriff (PDF)

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

Journal of thoracic oncology, 2014-03, Vol.9 (3), p.e27-e28

2014

Volltextzugriff (PDF)

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

International journal of clinical oncology, 2019-07, Vol.24 (7), p.731-770

2019

Volltextzugriff (PDF)

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

Current Treatment Options in Oncology, 2015-12, Vol.16 (12), p.56, Article 56

2015

Volltextzugriff (PDF)

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Pediatrics international, 2022-01, Vol.64 (1), p.e15106-n/a

2022

Volltextzugriff (PDF)

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Lung cancer (Amsterdam, Netherlands), 2018-03, Vol.117, p.14-19

2018

Volltextzugriff (PDF)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

OncoTargets and therapy, 2018-01, Vol.11, p.5093-5101

2018

Volltextzugriff (PDF)

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)

PloS one, 2021-10, Vol.16 (10), p.e0258616-e0258616

2021

Volltextzugriff (PDF)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

JTO clinical and research reports, 2022-06, Vol.3 (6), p.100332-100332, Article 100332

2022

Volltextzugriff (PDF)

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Journal of thoracic oncology, 2014-12, Vol.9 (12), p.e86-e87

2014

Volltextzugriff (PDF)

Dual effects of reversed winter–spring temperatures on year‐to‐year variation in the recruitment of chub mackerel (Scomber japonicus)

Fisheries oceanography, 2019-03, Vol.28 (2), p.212-227

2019

Volltextzugriff (PDF)

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

International journal of clinical oncology, 2022-09, Vol.27 (9), p.1404-1412

2022

Volltextzugriff (PDF)

Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration

The Annals of thoracic surgery, 2020-11, Vol.110 (5), p.e377-e379

2020

Volltextzugriff (PDF)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

Frontiers in oncology, 2022-10, Vol.12

2022

Volltextzugriff (PDF)

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

International journal of clinical oncology, 2022-12, Vol.27 (12), p.1828-1838

2022

Volltextzugriff (PDF)

NTRK Fusion-positive Non–small-cell Lung Cancer: The Diagnosis and Targeted Therapy

Clinical lung cancer, 2021-01, Vol.22 (1), p.1-5

2021

Volltextzugriff (PDF)

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Oncology and therapy, 2018-12, Vol.6 (2), p.203-215

2018

Volltextzugriff (PDF)

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Frontiers in oncology, 2021-08, Vol.11, p.704084-704084

2021

Volltextzugriff (PDF)

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data

BMC pulmonary medicine, 2022-01, Vol.22 (1), p.31-31, Article 31

2022

Volltextzugriff (PDF)

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.9007-9007

2018

Volltextzugriff (PDF)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation

Thoracic cancer, 2021-03, Vol.12 (6), p.978-980

2021

Volltextzugriff (PDF)

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Thoracic cancer, 2022-08, Vol.13 (15), p.2192-2200

2022

Volltextzugriff (PDF)

Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance

Respiratory investigation, 2014-11, Vol.52 (6), p.330-338

2014

Volltextzugriff (PDF)

Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study

Drugs -- real world outcomes, 2022-03, Vol.9 (1), p.63-78

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Crizotinib Can Overcome Acquired Resistance to CH5424802: Is Amplification of the MET Gene a Key Factor?

The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study)

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

Dual effects of reversed winter–spring temperatures on year‐to‐year variation in the recruitment of chub mackerel (Scomber japonicus)

Survival benefit of using pemetrexed for EGFR mutation-positive advanced non-small-cell lung cancer in a randomized phase III study comparing gefitinib to cisplatin plus docetaxel (WJTOG3405)

Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation

Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study

NTRK Fusion-positive Non–small-cell Lung Cancer: The Diagnosis and Targeted Therapy

Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan

Targeted Therapy for RET Fusion Lung Cancer: Breakthrough and Unresolved Issue

Concurrent chemoradiotherapy with cisplatin + S-1 versus cisplatin + other third-generation agents for locally advanced non-small-cell lung cancer: a meta-analysis of individual participant data

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation

Erlotinib with or without bevacizumab as a first‐line therapy for patients with advanced nonsquamous epidermal growth factor receptor‐positive non‐small cell lung cancer: Exploratory subgroup analyses from the phase II JO25567 study

Anaplastic lymphoma kinase rearrangement in lung Cancer: Its biological and clinical significance

Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study

Aktive Filter

Suchergebnisse filtern